Search
Phathom Pharmaceuticals Inc
PHATAdd to Watchlist
11.200USD
+0.665+6.31%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
799.89MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+6.31%
5 Days
+8.32%
1 Month
+16.06%
6 Months
-28.71%
Year to Date
-32.49%
1 Year
+25.70%
Key Figures
10.660Open
11.275High
889.30KVolume
LossP/E TTM
7.13P/E Dynamic
--Dividend TTM
1.25%Turnover Ratio
10.535Prev. Close
10.580Low
6.28MTurnover
LossP/E Static
-1.83P/B
0.00%Div Yield TTM
-52.49%ROA
18.31052wk High
1.28Volume Ratio
-334.33MNet Profit
71.42MShares
-2.0938EPS TTM
0.53Beta
-3489.00%ROE
4.05052wk Low
6.60%Amplitude
79.42%Gross Margin
799.89MMarket Cap
1.19Reward/Risk
3.69%Risk Rate
TradingKey Stock Score of Phathom Pharmaceuticals Inc
Currency: USD Updated: 2026-07-02Key Insights
Phathom Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 51 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 23.70.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Phathom Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Phathom Pharmaceuticals Inc Highlights
StrengthsRisks
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 25575.95% year-on-year.
Undervalued
The company’s latest PE is -5.35, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 69.84M shares, decreasing 16.93% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 86.89K shares of this stock.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
23.700
Target Price
+118.03%
Upside Space
Phathom Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Phathom Pharmaceuticals Inc Info
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Ticker SymbolPHAT
CompanyPhathom Pharmaceuticals Inc
CEOBasta (Steven)
Websitehttps://www.phathompharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52993.200
+150.700 (+0.28%)
29566.700
+255.300 (+0.87%)
7503.600
+32.100 (+0.43%)
15104.000
+301.000 (+2.03%)
69524.000
+1376.000 (+2.02%)
6377.300
+24.500 (+0.39%)
68.913
+0.569 (+0.83%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4177.870
+55.960 (+1.36%)
FAQs
What is the current price of Phathom Pharmaceuticals Inc (PHAT)?
The current price of Phathom Pharmaceuticals Inc (PHAT) is 11.20.
What is the symbol of Phathom Pharmaceuticals Inc?
The ticker symbol of Phathom Pharmaceuticals Inc is PHAT.
What is the 52-week high of Phathom Pharmaceuticals Inc?
The 52-week high of Phathom Pharmaceuticals Inc is 18.31.
What is the 52-week low of Phathom Pharmaceuticals Inc?
The 52-week low of Phathom Pharmaceuticals Inc is 4.05.
What is the market capitalization of Phathom Pharmaceuticals Inc?
The market capitalization of Phathom Pharmaceuticals Inc is 799.89M.
Is Phathom Pharmaceuticals Inc (PHAT) currently rated as Buy, Hold, or Sell?
According to analysts, Phathom Pharmaceuticals Inc (PHAT) has an overall rating of Buy, with a price target of 23.70.
What is the Earnings Per Share (EPS TTM) of Phathom Pharmaceuticals Inc (PHAT)?
The Earnings Per Share (EPS TTM) of Phathom Pharmaceuticals Inc (PHAT) is -3.03.